PathMaker Neurosystems
Boston, MassachusettsFounded 2015
- Neuromodulation
- ALS
PathMaker Neurosystems is a medical device company developing non-invasive neuromodulation treatments for ALS and other serious neurological disorders. Its Multi-Site DCS approach stimulates multiple points along neural pathways, with the goal of restoring damaged pathways and slowing ALS progression.
- TrialClinical trial
- 1
- Founded
- 2015
- Employees
- 1–10
reccy insights
PathMaker’s recent milestones have centered on advancing its investigational MyoRegulator® program for ALS. On January 12, 2026, the company announced completion of an ALS early-feasibility study of the device. In December 2025, MyoRegulator received FDA Breakthrough Device Designation for use in ALS, with the stated aim of slowing progression of functional symptoms; the designation is not FDA marketing authorization. In July 2025, PathMaker announced publication of a study reporting increased survival in an ALS mouse model following non-invasive neuromodulation, a preclinical result that does not establish clinical benefit. Earlier, on June 2, 2025, it announced RI Life Science Hub funding to establish operations in Rhode Island, adding a geographic expansion milestone to its Boston base. In March 2025, the company announced issuance of three patents related to its ALS neuromodulation technology, and in February 2025 it reported IRB approval for a Department of Defense-funded ALS clinical trial. Together, these developments show progress across research, intellectual property, clinical execution and regional operations, while the device remains investigational.
Written by reccy's AI from company sites, press and funding records · updated Oct 2026
What makes PathMaker Neurosystems distinct
- 01Uses synchronized stimulation at multiple sites along neural pathways rather than relying on single-site stimulation.
- 02Developed the investigational MyoRegulator® device for ALS clinical studies, with a broader focus on neurological disorders.
- 03DoubleStim® technology is described as covered by more than 40 issued patents across the United States, Europe and other territories.
- 04Aims to modulate neural activity and address damaged neural pathways through non-invasive neuromodulation.
Technology & products3
- MyoRegulator®
An investigational, non-invasive neuromodulation device for reducing muscle spasticity associated with stroke and other neurological disorders through synchronized spinal and peripheral direct-current stimulation.
- MyoRegulator® ALS
An investigational non-invasive neuromodulation program for ALS designed to suppress motor-neuron hyperexcitability and potentially address disease-related neural dysfunction.
- Multi-Site DCS Technology
A proprietary neuromodulation technology that applies synchronized direct-current stimulation at multiple neural sites to modulate abnormal neural activity without surgery.
Clinical trials1
- Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability StudyRecruitingNCT06649955 · 15 participants · started Feb 2025
- ALS - Amyotrophic Lateral Sclerosis
Recent updates2
- Dec 17, 2025Product launch
PathMaker Neurosystems received FDA Breakthrough Device Designation for its investigational MyoRegulator neuromodulation device, a non-invasive treatment aimed at slowing progression of functional symptoms in ALS patients, which is currently being evaluated in the CALM clinical trial.
globenewswire.com - Dec 17, 2025Award
FDA Breakthrough Device Designation for MyoRegulator in ALS
Similar companies
About PathMaker Neurosystems
- Products
- MyoRegulator®, MyoRegulator® ALS, Multi-Site DCS Technology
- Leadership
- Nader Yaghoubi, Co-Founder and Chief Executive Officer
- Focus areas
- Neurotechnology, medical devices, neuromodulation, ALS, neurological disorders, clinical-stage, bioelectronic medicine
- Headquarters
- Boston, Massachusetts
- Founded
- 2015
- Employees
- 1–10
- Patents granted
- 2 (Crunchbase)
- Trademarks
- 7